MetaCap

PROCEPT BioRobotics (PRCT) vs SI-BONE (SIBN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SI-BONE (SIBN) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 21.7% versus a loss of 17.3%. Over five years, SIBN leads with a +18.5% price change compared with -30.6% for PRCT. PROCEPT BioRobotics is the larger company by market cap ($1.42 billion vs $1.07 billion), about 1.3 times the size.

SI-BONE converts more of its revenue into profit, with a net margin of -9.4% versus -31.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PRCT-17.28%SIBN+21.69%
+35%-6%-48%
Nov 21, 20251 yearNov 20, 2026
PRCT-39.28%SIBN+11.72%
+154%+42%-69%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PRCT versus SIBN key metrics
MetricPRCTSIBN
Share price$24.70$23.73
Market cap$1.42B$1.07B
1-day change-4.08%-0.08%
YTD return-21.49%+20.33%
1-year return-17.28%+21.69%
5-year return-30.64%+18.53%
EPS (TTM)$-2.02$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$308.05M$200.93M
Revenue growth (YoY)+37.22%+20.19%
Net income (latest FY)$-95.57M$-18.90M
Gross margin63.70%79.57%
Operating margin-33.71%-11.11%
Net margin-31.02%-9.41%
52-week high$38.11$25.92
52-week low$16.67$11.48
Distance from 52-week high-35.19%-8.45%
Analyst consensusholdstrong_buy
Avg. price target upside-7.89%+12.85%
Average volume1.31M709.79K
Shares outstanding57.54M45.11M
Employees888376
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SIBN has outperformed PRCT by 39.0 percentage points over the past year.
  • SI-BONE is more profitable, keeping -9.4 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
  • PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs +20.19%).

About PROCEPT BioRobotics

PRCT stock →

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.

Health Care · Medical/Dental Instruments · 888 employees

About SI-BONE

SIBN stock →

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.

Health Care · Medical/Dental Instruments · 376 employees

PRCT vs SIBN FAQ

Which is bigger, PROCEPT BioRobotics or SI-BONE?

PROCEPT BioRobotics (PRCT) is larger, with a market capitalization of $1.42B compared with $1.07B for SI-BONE (SIBN).

Which stock has performed better over the past year, PRCT or SIBN?

SIBN returned +21.69% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.

Are PROCEPT BioRobotics and SI-BONE in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons